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The chains of habit are too weak to be felt 
until they are too strong to be broken 
Samuel Johnson 
1. Introduction 
Obsessive-compulsive disorder is a common chronic neuropsychiatric illness. Estimates of 
the lifetime prevalence rate of obsessive-compulsive disorder will vary depending on the 
methods used to gather the epidemiological data and the diagnostic criteria used to define 
obsessive-compulsive disorder. Estimates of the lifetime prevalence of obsessive-compulsive 
disorder have been reported to be to be between 1.9%-3.3%, when obsessive compulsive 
disorder was defined without DSM-III criteria. A slightly lower prevalence of obsessive-
compulsive disorder was reported to be between 1.2%-2.4%, when obsessive-compulsive 
disorder was defined using DSM-III criteria123. These estimates of the prevalence of 
obsessive-compulsive disorder are likely to be accurate because they are based on: a.) 
population-based data; b.) that was gathered from five US communities; c.) from more than 
18,500 outpatients; participating in the NIMH Epidemiologic Catchment Area (ECA) a 
Study. The lifetime prevalence rates obtained from the NIMH ECA study were 25-60 times 
higher than previous estimates, which were based on studies of clinical populations. If the 
true lifetime prevalence of OCD in the United States is 2.5%, then it follows that 6.5 million 
Americans will be affected by obsessive-compulsive disorder during their lifetime. If the 1-
month prevalence rate of OCD in the United States is 1.3 %, then approximately 3.4 million 
Americans suffer from obsessive compulsive disorder each Month4. Regardless of the 
specific epidemiological and diagnostic methods used to estimate the incidence or 
prevalence of obsessive-compulsive disorder, literally millions of Americans are affected by 
the symptoms. 
There is strong evidence that obsessive-compulsive disorder impacts the American economy 
measureably. This premise is supported by the following. First, medical costs, yearly, from 
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obsessive-compulsive disorder have been estimated to be $2.1 billion. Second, indirect costs 
due to lost productivity have been estimated to be $5.9 billion5. Third, health care 
expenditures in the United States surpassed $2.3 trillion in 2008, were $714 billion spent in 
1990, and equalled $253 billion in 19806., Therefore, it is highly likely that both the direct 
and indirect costs of obsessive-compulsive disorder continue to increase.  
Economic indicators non-withstanding, the broader impact of obsessive-compulsive 
disorder on social, educational, and occupational function was addressed in a recent study. 
The  investigators found that the symptoms of obsessive-compulsive disorder affected 
socialization by various means. Lowered self-esteem was observed in 92% of patients 
sampled, interference with family relationships reported in 73% of patient’s sampled, and 
difficulty maintaining relationships was noted by 62% of patients7. Lowered academic 
achievement was observed in 58% of patients with obsessive-compulsive disorder, 
indicating that the disorder profoundly impacts educational achievement7. Occupational 
functioning is also affected in patient’s with obsessive-compulsive disorder, through: 
lowered career aspirations, observed in 66% of patients sampled; work interference in 47% 
of patient’s sampled, and ; lost time due to inability to work, reported in 40% of patients7.  
Suicide is the most serious complication of anxiety disorders. Suicide attempts secondary to 
obsessive-compulsive disorder symptoms have been reported in 13% of patients7. 
Obviously, if a suicide attempt is completed, progress in all three important areas of life 
function—relationships, educational and vocational function—halt permanently. Harm to 
family members through related injury, bereavement, lost spousal support, childhood 
parentification, and impact on the surrounding community is also significant after a 
completed suicide. In 2008, a total of 36,035 persons died as a result of suicide and in the 
United States approximately 666,000 persons visited hospital emergency departments for 
nonfatal, self-inflicted injuries8. Although suicidal thoughts do not always lead to a lethal or 
life threatening suicide attempt, suicidal thoughts and behavior even in the absence of 
suicide attempt are important. Public health surveillance is performed on suicide-related 
issues by gathering data at the state level by a national- and state-level survey—the National 
Survey on Drug Use and Health (NSDUH). Between January 1, 2008–December 31, 2009, the 
NSDUH obtained data from 92,264 respondents, a representative sample of the civilian, 
noninstitutionalized U.S. population aged ≥12 years, of various race/ethnicity. In 2008 and 
2009, an estimated 8.3 million (annual average) adults aged ≥18 years in the United States 
(3.7% of the adult U.S. population) reported having suicidal thoughts in the past year8. An 
estimated 2.2 million (annual average) adults in the United States (1.0% of the adult U.S. 
population) reported having made suicide plans in the past year8. An estimated 1 million 
(annual average) adults in the United States (0.5% of the U.S. adult population) reported 
making a suicide attempt in the past year8. The prevalence of suicidal thoughts, suicide 
planning, and suicide attempts was significantly higher among young adults aged 18–29 
years than it was among adults aged ≥30 years8. The prevalence of suicidal thoughts was 
significantly higher among females than it was among males, but there was no statistically 
significant difference for suicide planning or suicide attempts8. Although the NSDUH did 
not attempt to gather data according diagnosis, as indicated above, suicide is a primary 
comorbidity of mood and anxiety disorders. Therefore, the premise that obsessive 
compulsive disorder has a large impact through its direct and indirect economic costs, as 
well as its broader social consequences, is significant is ample. 
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However, the symptoms of obsessive-compulsive disorder are experienced at the level of 
the individual patient. It is at the level of the individual patient, that anyone can identify 
with symptoms of obsessive-compulsive disorder. The experience of intrusive, obsessive 
thoughts—wondering if the stove was left on or the front door was left unlocked while 
driving away from home—and compulsive behavior—being compelled to return home and 
check the stove or the door—is very common.  
Obsessive-compulsive disorder is currently defined by the presence of obsessions and 
compulsions. Obsessions are recurrent, unwelcome thoughts, that may include: fear of dirt, 
germs, contamination; fear of acting on violent or aggressive impulses; feeling overly 
responsible for the safety of others; abhorrent religious and sexual thoughts, and/or; 
inordinate concern with order, arrangement and symmetry. Compulsions are repetitive 
behaviors that are performed in response to obsessions, in order to lessen the distress 
caused by obsessions. The short-term gain of reduced anxiety comes at a long-term cost of 
frequent repetition of these behaviors. Compulsions may affect social and occupational 
function to a profound degree as described above.  
The professional community defines the diagnosis of obsessive-compulsive disorder, using 
criteria outlined in the DSM-IV9. The diagnosis of obsessive-compulsive disorder using 
modern criteria requires:  the presence of obsessions and/or compulsions; recognized as 
excessive or unreasonable; causing marked distress, time-consumption (>1 hour/day), or 
interference with functioning. The obsessions and compulsions cannot be due to another 
Axis I psychiatric disorder, due to substance abuse, substance dependence, substance 
withdrawal, or due to a medical condition. For example, an individual with obsessive-
compulsive disorder may be besot by unwanted and inappropriate sexual thoughts about 
neighbors, coworkers or family members, and will attempt to “undo” the obsessions by 
compulsive checking. Similarly, and individual with recurrent obsessions about the fact that 
they may have harmed individuals, which the patient tries to “undo”, by returning over and 
over to the place where the thought occurred. Alternatively, a patient with obsessive-
compulsive disorder may have constant thoughts that they are sinful, which the patient 
attempts to undo with repetitive prayer. Those who suffer from obsessive-compulsive 
disorder may be unable to carry out their responsibilities: at work, leading to 
unemployment; at home, resulting in marital conflict as well as disturbed family 
relationships, and; in society, leading to social isolation. The disruption of normal social and 
emotional development in obsessive-compulsive disorder not unlike that experienced in 
other neurodevelopmental disorders, such as schizophrenia. Like schizophrenia, there is 
likely both a genetic and environmental contributors to obsessive-compulsive disorder10. 
The altered life trajectory of these illnesses is quite sobering.  
The two current effective treatments for patients with obsessive-compulsive include 
cognitive behavioral therapy (CBT) and pharmacotherapy. CBT consists of a technique 
called exposure and response prevention, in which patients deliberately and voluntarily 
expose themselves to fears/ideas, but are discouraged from carrying out compulsive 
responses. Studies do show successful results for extended periods of time. CBT can fail for 
various reasons, including, poorly executed treatments; patient or family noncompliance, 
psychiatric comorbidity such as severe depression or a personality disorder, poor insight 
(~5% of patients) or severe illness. CBT requires patients that are highly motivated, 
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cooperative, and diligent, and is more likely to be successful when combined with 
pharmacotherapy. Traditional psychotherapy generally not helpful as a stand-alone therapy 
for OCD symptoms, although it is appropriate for the ongoing difficulties with adjustment 
experienced by patients with obsessive-compulsive disorder.  
With respect to pharmacotherapy, specific medications have shown some effectiveness in 
controlling the symptoms of obsessive-compulsive disorder, including: SSRIs (selective 
serotonin reuptake inhibitors) such as Fluvoxamine, Fluoxetine, Sertraline, Paroxetine, 
Citalopram, ES Citalopram; SNRIs (serotonin-norepinephrine reuptake inhibitors) such as 
venlafaxine, and; TCAs (tricyclic antidepressants) such as Clomipramine. Treatment 
resistance or treatment-refractory obsessive-compulsive disorder is said to occur when 
patients with obsessive-compulsive disorder fail to benefit from treatment. By 
conservative estimate, 5% of patients with obsessive-compulsive disorder are treatment 
resistant. If 5% of Americans have treatment-refractory obsessive-compulsive disorder, 
then according to the aforementioned monthly or yearly prevalence rates, then 170,000 
Americans each month, or 325,000 Americans in their lifetime are afflicted with treatment 
resistant obsessive-compulsive disorder. Treatment options for these patients are very 
limited.  
2. Orbitofrontal-striatal function 
The importance of brain circuits connecting frontal lobe to the basal ganglia was first 
observed in primates by Alexander and colleagues11, who reported evidence for an 
anatomically distinct lateral orbitofrontal circuit loop, comprised of projections from: 
orbitofrontal cortex to the head of the caudate nucleus and the ventral striatum; to the 
internal pallidus; to the mediodorsal thalamus; returning from the thalamus to the 
orbitofrontal cortex. Alexander and colleagues hypothesized: the existence of several 
relatively specialized fronto-striatal loops; proposed that they were organized in parallel, 
linking the basal ganglia to the frontal cortex, and; that each circuit played a functional role 
based on its connections to particular regions of the frontal cortex. Other investigators12, 13 
have suggested that the so-called “limbic” structures (i.e.—hippocampus, anterior cingulate 
and, basolateral amygdala) ought to include in the lateral orbitofrontal circuit loop circuit, 
because of their extensive connections to the orbitofrontal cortex. Based on these 
interconnections, it can be hypothesized that this “greater” lateral orbitofrontal circuit could 
play a role in emotion, as the function of these so-called “limbic” brain regions play a role in 
affective states and emotional perception. 
The orbitofrontal cortex is a key brain region, not only in emotional behavior, but also for 
motivation 14-18. This was first shown by Harlow19 who provided a naturalistic description of 
profound changes in behavior of a 19th century railway worker— Phineas Gage—after a 
charge he was setting, using a tamping rod exploded. He sustained a severe left frontal lobe 
injury, after the tamping rod was when a was launched through his forehead and out his 
skull. Reported changes in Gage’s behavior following the accidental orbitofrontal cortex 
damage included not only inappropriate emotional responses, but also, impulsive and 
poorly thought out decisions, characteristic of behavioral changes in patients with 
orbitofrontal cortex lesions20, 21 22.  
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Since learning-based motivation requires the integration of complex brain systems that 
include orbitofrontal cortex, researchers have hypothesized that difficulties “unlearning” 
reinforced behaviors may be associated trouble with sensing change between behavior-
reward relationships. Impairment in the unlearning of established reward-motivated 
behaviors are also observed in animals and humans with orbitofrontal cortex lesions 23 24 25. 
Furthermore, patients with focal lesions either in the striatum or the ventral palladium, (an 
area it projects to) demonstrate behaviors very consistent with those observed in obsessive-
compulsive disorder26, 27.  
The results of functional imaging research have provided complementary evidence to the 
lesion studies demonstrating that the orbitofrontal cortex is a key brain region involved in 
learning and motivation. The human brain’s awareness of expecting a reward and the 
likelihood that a reward will occur is requires an intact orbitofrontal cortex28-30. If the 
orbitofrontal cortex is not intact, a person’s behavior may seem impulsive or they may 
appear to have poor judgment.  
The orbitofrontal cortex may have anatomically and functionally segregated orbitofrontal-
thalamic striatal circuits. This idea of Alexander and colleagues is supported by research 
indicating that the lateral orbitofrontal cortex may have a distinct and separate function 
from medial orbitofrontal cortex, in that the lateral orbitofrontal cortex was activated when 
suppressing a response already associated with a reward 31. This would imply that 
dysfunction of the lateral orbitofrontal cortex prevents inhibition of behavior reinforced 
previously by a reward.  
3. Evidence for orbitofrontal-striatal dysfunction in obsessive-compulsive 
disorder 
The current most popular model proposed by researchers to explain the neurobiological 
foundation of obsessive-compulsive disorder focuses on abnormalities in cortical-striatal-
thalamic circuitry—the orbitofrontal-striato-thalamic circuits in particular32-34.  
3.1 Evidence from neuroimaging studies 
Using techniques that measure brain glucose metabolism, fluorodeoxyglucose positron-
emission tomography (FDG PET), investigators demonstrated increased cerebral glucose 
metabolism present bilaterally in the cerebral hemispheres and orbitofrontal gyrii, as well as 
both caudate heads, in patient with OCD patients35 36. The findings were replicated37-42 in 
FDG-PET studies examining patients both at rest, and while provoking symptoms, although 
not all studies produced positive findings43-45. A meta-analysis46 confirmed abnormalities 
were present in the orbital gyrus and the head of the caudate in patients with obsessive-
compulsive disorder. The results of PET studies are an important piece of supportive 
evidence of the orbitofrontal-striato-thalamic model. 
3.2 Evidence from deep brain stimulation research 
Another strong piece of evidence supporting this model is the symptomatic improvement of 
patients with obsessive-compulsive disorder undergoing capsulotomy. Focal lesioning 
www.intechopen.com
 
When Things Go Wrong – Diseases and Disorders of the Human Brain 116 
during a surgical procedures for neuropsychiatric disorders has been known as 
“psychosurgery”. Historically, these procedures have been thought not to be discriminate in 
terms of neuroanatomical location or groups of patients treated47-49. Furthermore, informed 
consent is thought not to be properly obtained, a process which requires careful assessment 
of an individual’s capacity to weigh the risks and benefits of an experimental medical or 
surgical procedure50. Consequently, psychosurgery is not viewed in a positive light in the 
popular media 51.  
Neurosurgery for psychiatric disorders is a highly invasive treatment. However, it is 
important to view these interventions in the proper historical context. Prior to 1950, 
psychiatric illness was essentially untreatable, as no specific medications existed for the 
treatment of severe psychiatric disorders. Since these illnesses were disabling and lethal, the 
treatments pursued were aggressive and invasive. These interventions included malarial 
pyrotherapy described by Epstein in 193652, hypoglycemic coma described by Sakel in 
193753, electroconvulsive therapy, described by Bini in 193854, as well as neurosurgery. 
Historically (and currently) the use of neurosurgery has only been used only for intractable 
psychiatric illnesses55.  
Burckhardt first published a report of the first (unsuccessful surgical attempts to treat severe 
psychosis in 189156. The first neuroanatomical models describing both function and 
structural of mood and behavioral regulation were published by Papez in 193757. At this 
time, a hypothesis was proposed by researchers that abnormal mood and behavioral 
regulation was caused by dysfunctional thalamo-cortical communication58, leading to the 
use of the prefrontal leucotomy (popularly known as the prefrontal lobotomy), a procedure 
that disrupted white matter tracts connecting these regions. Because the ability of surgeons 
to localize and severing specific frontal lobe white matter tracks, lesions were 
indiscriminantly large. After 1950, pharmacologic interventions were identified that 
drastically reduced the symptoms of psychiatric disorders. The pharmacology revolution of 
the mid-twentieth-century resulted in the discovery of medications effective: for mania 
described by Cade in 1949 and Schou and colleagues in 195459, 60; for psychosis described by 
Bower in 195461, and Winkelman in 195462, and; for depression described by Bailey and 
colleagues in 195963, Kiloh and colleagues in 196064, and Kuhn in 195865.  
In the early 1960s, investigators reported that stimulation of different brain area induced 
hypomania, dysphoria, and anhedonia. These early findings suggested the possible efficacy 
of DBS in treatment refractory psychiatric disorders. One of the earliest anatomically specific 
psychosurgery consists of ablation of the anterior limb of the internal capsule—the anterior 
capsulotomy—was found to be efficacious in severely refractory obsessive-compulsive 
disorder. The first anterior capsulotomies were performed in Europe in the late 1940’s. 
During the procedure, symmetric bilateral lesions are made in the anterior limb of the 
internal capsule, which is quite near to the ventral striatum. This lesion, whether made by 
heat (thermocoagulation during neurosurgery or a thermocapsulotomy) or by minimally 
invasive gamma irradiation (a gamma-capsulotomy), interrupts the passage of white matter 
fibers between the prefrontal cortex and the subcortical nuclei, the striatum, and the 
dorsomedial thalamus. A recent prospective study of 35 patients with obsessive-compulsive 
disorder who underwent thermocapsulotomy showed that that 70% had “satisfactory 
outcomes” after 3 years66.  
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The recent development of deep brain electrode placement at the ventral capsule/ventral 
striatum (VC/VS) target is also a very strong piece of evidence supporting this model. 
Deep brain stimulation is a reversible, neurosurgical procedure. Deep brain stimulation is 
an invasive neurosurgical intervention being used to treat psychiatric disorders in an 
investigative fashion. The disorders currently being examined include treatment-resistant 
major depressive diosrder, treatment-resistant obsessive-compulsive disorder, Tourette’s 
Syndrome, Alzheimer’s dementia, and addictions. The actual treatment consists of 
implanting one or more electrode leads into a particular brain regions through burr holes 
in the skull using a proprietary stereotactic neurosurgical techniques. Neuroimaging-
guided implantation calculates the route to the target using a three-dimensional 
coordinate system based on external landmark. Current commercially available leads 
have four electrodes, 1-2 mm in length, separated by 4-5 mm, the complete electrode 10–
20 mm in length. The leads connect to subcutaneous extension wires that are tunnelled 
surgically to pulse generators implanted in the chest. The pulse generators contain a 
battery and hardware/software that drives the neurostimulation. A programmer can set 
the programs in the neurostimulator using a handheld computer with a wireless 
connection. 
In the 1960s electrical stimulation of the ventrolateral thalamus was noted to stop tremor. 
Prolonged electrical stimulation at different targets was found to be effective for treatment-
refractory movement disorders, epilepsy, chronic pain and tremor. Investigators then 
delivered high frequency cathodic (positive ) electrical stimulation directly at the surgical 
target, in order to mimic the effect of a surgical lesion 67, 68, leading to the development of 
technology first used clinically in Parkinson’s disease, essential tremor, and extrapyramidal 
dyskinesias. Currently, there are many numerous published reports demonstrating the 
safety and efficacy of DBS for intractable movement disorders69, 70.  
In fact, the efficacy and safety data from studies in patients with movement disorders led 
the FDA to approve the use of obsessive-compulsive disorder for essential tremor and 
Parkinson’s disease. The FDA eventually approved the use of DBS for dystonia under a 
Humanitarian Device Exemption (HDE). The results of a recent open label clinical trial of 
DBS using the VC/VS target suggested that DBS for intractable obsessive-compulsive 
disorder had encouraging therapeutic effects, with probable benefit even 3 years after 
surgery 71. The specificity of this lesion is the strongest piece of evidence supporting the 
dysfunction of orbitofrontal-striato-thalamic circuits as a likely etiology of obsessive-
compulsive disorder.  
3.3 Summary and conclusions 
Obsessive-compulsive disorder is a serious neuropsychiatric illness. Treatment-resistant 
obsessive-compulsive disorder is less common, but highly debilitating. The evidence for the 
role of orbitofrontal-striato-thalamic circuits in mediating emotion, learning, and reward-
focused behavior is strong. The evidence that these important brain systems are 
dysfunctional in patients with obsessive-compulsive disorder is also strong. Expanding 
knowledge about these brain circuits will provide a rich area for further research and is 
necessary to develop effective treatments for obsessive-compulsive disorder.  
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